FDA Rejects Citius Bid Replace Ontak With Lymphir

FDA Rejects Citius Bid to Replace Ontak With Lymphir

Recently, Citius Pharmaceuticals faced a significant setback when the U.S. Food and Drug Administration (FDA) rejected their application for Lymphir…